Q-omics provides the consensus-scored DUX4L19 profile across patient tissues and cancer cell-line models. DUX4L19 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in UCEC. Additionally, DUX4L19 RNA expression shows 5,254 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, and STAD as cancer lineages where DUX4L19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.